Global mRNA Sequencing Market Size By Type (PCR, Microarray), By Application (Pharmaceutical and Biotechnology, Academic Research and Government Institutes), By Region, And Segment Forecasts, 2023 to...

The Global mRNA Sequencing Market was valued at USD 1.9 billion in 2023 and is expected to reach USD 6.3 billion by 2031, expanding at a CAGR of 16.1% from 2023 to 2031. The market's growth is fueled by the rising demand for high-throughput sequencing in precision medicine, growing applications in transcriptomics research, and the increasing use of mRNA sequencing in vaccine development, particularly after the success of mRNA-based COVID-19 vaccines.

mRNA sequencing has become a cornerstone in understanding gene expression, uncovering disease mechanisms, and developing targeted therapeutics. As research institutions and pharmaceutical companies increase investments in genomics, the mRNA sequencing market is poised for significant growth.

Drivers:

1. Advancements in Next-Generation Sequencing (NGS) Technology:

Technological improvements in NGS have enhanced the accuracy, speed, and affordability of mRNA sequencing, leading to broader adoption in both academic and clinical settings.

2. Rising Demand for Personalized Medicine:

mRNA sequencing enables in-depth transcriptome analysis, supporting the development of personalized treatments based on gene expression profiles. The push toward precision medicine is a major driver for market growth.

3. Growing Investments in Genomics Research:

Governments and private entities worldwide are increasing funding for genomics and biotechnology, directly contributing to the demand for advanced sequencing technologies, including mRNA sequencing.

Restraints:

1. High Cost of Equipment and Sequencing Protocols:

Despite declining costs, mRNA sequencing still requires expensive instruments and reagents, posing a barrier for small laboratories and institutions in developing regions.

2. Data Interpretation Complexity:

Analyzing large volumes of sequencing data requires advanced bioinformatics tools and expertise, which not all organizations possess, thereby limiting widespread use.

Opportunity:

1. Expanding Applications in Infectious Disease Research and Vaccine Development:

The success of mRNA-based COVID-19 vaccines has highlighted the potential of mRNA sequencing in virology and immunology, creating opportunities for its application in emerging infectious diseases.

2. Integration with Artificial Intelligence and Cloud-Based Platforms:

Leveraging AI and cloud technologies can streamline the analysis of mRNA sequencing data, increasing accessibility and efficiency for end-users and opening new commercial possibilities.

Market by System Type Insights:

The platform-based sequencing segment led the market in 2023, owing to its ability to process thousands of samples simultaneously with high precision. Illumina, Oxford Nanopore, and PacBio platforms dominate this segment due to their scalability and application diversity. However, the reagent & consumables segment is expected to grow rapidly, driven by increasing sample volumes and recurring purchases.

Market by End-use Insights:

In 2023, academic and research institutes held the largest market share due to widespread utilization of mRNA sequencing in basic and translational research. Meanwhile, the pharmaceutical and biotechnology companies segment is projected to exhibit the highest CAGR during the forecast period, driven by increasing use of mRNA sequencing in drug discovery and vaccine development pipelines.

Market by Regional Insights:

North America dominated the global mRNA sequencing market in 2023, backed by well-established genomic infrastructure, substantial R&D investments, and leading sequencing companies. Asia-Pacific is expected to witness the fastest growth due to increasing genomics research funding in countries like China, India, and Japan, along with a growing biotechnology sector.

Competitive Scenario:

Key players in the global mRNA sequencing market include Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, BGI Genomics, Pacific Biosciences, PerkinElmer, QIAGEN, Takara Bio Inc., and Oxford Nanopore Technologies. These companies are focused on technological innovation, strategic acquisitions, and expanding service portfolios. Notable developments include:

2024: Illumina launched a faster, more affordable NGS platform optimized for mRNA sequencing in clinical diagnostics.

2023: Thermo Fisher introduced AI-powered bioinformatics tools integrated with its mRNA sequencing kits.

2023: QIAGEN partnered with a global research consortium to develop mRNA sequencing assays for rare disease studies.

Scope of Work – Global mRNA Sequencing Market

Key Market Developments:

Illumina unveiled a compact sequencing device tailored for decentralized mRNA expression analysis (2024).

Oxford Nanopore partnered with academic institutions in Asia to promote mRNA transcriptome mapping (2023).

BGI Genomics launched a turnkey solution for single-cell mRNA sequencing applications (2023).

FAQs:

1) What is the current market size of the Global mRNA Sequencing Market?

The market size was valued at USD 1.9 billion in 2023.

2) What is the major growth driver of the Global mRNA Sequencing Market?

The key driver is the rising demand for precision medicine and mRNA-based vaccine development.

3) Which is the largest region during the forecast period in the Global mRNA Sequencing Market?

North America is the largest region, supported by strong R&D infrastructure and key market players.

4) Which segment accounted for the largest market share in Global mRNA Sequencing Market?

The platform-based sequencing segment led the market in 2023.

5) Who are the key market players in the Global mRNA Sequencing Market?

Major players include Illumina Inc., Thermo Fisher Scientific, BGI Genomics, Agilent Technologies, and Oxford Nanopore Technologies.